Tirzep Injection 2.5 mg/0.5 ml contains Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is designed for the management of type 2 diabetes mellitus (T2DM) in adults to improve blood glucose control. By targeting both GIP and GLP-1 pathways, Tirzepatide enhances insulin secretion, reduces glucagon release, and slows gastric emptying, leading to improved glycemic control and potential weight reduction.

Tirzepatide represents a breakthrough in diabetes management with its dual-action mechanism, offering effective glucose lowering with additional benefits on body weight and metabolic health.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Tirzep Injection is indicated for:

• Adults with type 2 diabetes mellitus requiring improved glycemic control
• Adjunct therapy for patients not adequately controlled with diet and exercise
• Can be used alone or in combination with oral antihyperglycemic medications
• Patients aiming for weight management as part of diabetes care

Mechanism of Action

Tirzepatide is a dual GIP and GLP-1 receptor agonist that works by:

• Stimulating insulin secretion in response to elevated blood glucose
• Suppressing glucagon release, reducing hepatic glucose production
• Slowing gastric emptying, improving postprandial glucose control
• Reducing appetite, potentially aiding in weight loss

This multimodal approach results in better overall glycemic control and metabolic benefits.

Dosage and Administration

• Administered as a subcutaneous injection once weekly.
• Starting dose: 2.5 mg per 0.5 ml once weekly, with titration as per physician guidance.
• Inject into the abdomen, thigh, or upper arm. Rotate injection sites to reduce skin irritation.
• Do not mix with other insulin or injectable medications.
• Follow the schedule strictly to maintain consistent blood glucose control.

Benefits

• Effective reduction of HbA1c levels in type 2 diabetes
• Supports weight reduction as part of glycemic management
• Once-weekly dosing improves adherence and convenience
• Reduces postprandial and fasting blood glucose levels
• Dual GIP/GLP-1 action provides superior metabolic control compared to single-agent therapy

Side Effects

Common side effects may include:

• Nausea and vomiting
• Diarrhea or constipation
• Injection site reactions (redness, itching, or swelling)
• Decreased appetite

Serious but rare side effects:

• Hypoglycemia, particularly when combined with insulin or sulfonylureas
• Pancreatitis (persistent severe abdominal pain)
• Allergic reactions or anaphylaxis

Seek immediate medical attention if severe reactions or symptoms of pancreatitis occur.

Precautions and Warnings

• Not recommended for patients with type 1 diabetes or diabetic ketoacidosis.
• Use with caution in patients with a history of pancreatitis or severe gastrointestinal disease.
• Monitor for thyroid tumors; Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma.
• Pregnancy and breastfeeding should only use under medical supervision.
• Regular blood glucose monitoring is essential, especially when combined with other antihyperglycemic agents.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

Tirzep Injection may interact with:

• Other antidiabetic medications (risk of hypoglycemia)
• Oral medications with narrow therapeutic indices (due to delayed gastric emptying)
• Drugs affecting gastrointestinal motility

Always inform your healthcare provider about all medications and supplements being taken.

Storage

• Store in a refrigerator at 2–8°C; do not freeze
• Keep away from direct sunlight and heat
• Keep out of reach of children
• Do not use after the expiration date
• Once opened, use within the period specified in the package insert.